Search Cancer Clinical Trials

The Cancer Center offers patients access to a wide variety of clinical trials of promising new therapies. Use the search tool to find open protocols for your type of cancer.
9 results
  • Bladder Cancer, Lymphoma, Lung Cancer, Melanoma, Kidney Cancer

21-481          Phase I

A First-in-Human, Multicenter, Open-Label, Phase 1 Dose-Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAB004 as Monotherapy and in Combination with Toripalimab in Subjects with Advanced Solid Malignancies including Lymphoma (View details on clinicaltrial.gov)

  • Liver Metastases, Thyroid Cancer, Kidney Cancer

21-511          Phase II

A Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-21822 Monotherapy and Combination Therapy in Adult Patients with Advanced Solid Tumors Harboring KRAS G12C Mutation (View details on clinicaltrial.gov)

  • Ovarian Cancer, Lung Cancer, Melanoma, Head and Neck Cancer, Kidney Cancer, Bladder Cancer, Breast Cancer

21-329          Phase II

A Phase 1a Open-Label, Dose-Escalation, and a Phase 2 Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of ST-067 Administered Subcutaneously as Monotherapy in Patients with Relapsed or Refractory Solid Tumors (View details on clinicaltrial.gov)

  • Kidney Cancer

20-741          Phase II

A PHASE 1B/2 , STUDY OF AVB-S6-500 IN COMBINATION WITH CABOZANTINIB AND AVB-S6-500 IN COMBINATION WITH CABOZANTINIB AND NIVOLUMAB, AND AVB-S6-500 MONOTHERAPY IN PATIENTS WITH ADVANCED OR METASTATIC CLEAR CELL RENAL CELL CARCINOMA (View details on clinicaltrial.gov)

  • Kidney Cancer

21-486          Phase I

A Phase I/Ib, open-label, multi-center study of DFF332 as a single agent and in combination with Everolimus or IO agents in patients with advanced/relapsed ccRCC and other malignancies with HIF2a stabilizing mutations (View details on clinicaltrial.gov)

  • Kidney Cancer

20-236          Phase I

An Open-label, Dose Escalation, Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-676 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced or Metastatic Solid Tumors (View details on clinicaltrial.gov)

  • Kidney Cancer

21-172          Phase III

An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Belzutifan (MK-6482) and Lenvatinib (MK-7902), or MK-1308A in Combination with Lenvatinib, versus Pembrolizumab and Lenvatinib, as First-line Treatment in Participants with Advanced Clear Cell Renal Cell Carcinoma (ccRCC) (View details on clinicaltrial.gov)

  • Melanoma, Kidney Cancer, Ovarian Cancer

22-062          Phase II

IL Believe: A Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study to Investigate the Safety and Tolerability of TransCon IL-2 ß/¿ Alone or in Combination with Pembrolizumab or Standard of Care Chemotherapy in Participants Aged 18 Years or Older with Locally Advanced or Metastatic Solid Tumor Malignancies (View details on clinicaltrial.gov)

Showing 1 - 10 of 9 results